

Mathew J Garnett

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3649486/publications.pdf>

Version: 2024-02-01

55
papers

13,688
citations

117625

34
h-index

149698

56
g-index

79
all docs

79
docs citations

79
times ranked

19479
citing authors

#	ARTICLE	IF	CITATIONS
1	Effective drug combinations in breast, colon and pancreatic cancer cells. <i>Nature</i> , 2022, 603, 166-173.	27.8	154
2	A suspension technique for efficient large-scale cancer organoid culturing and perturbation screens. <i>Scientific Reports</i> , 2022, 12, 5571.	3.3	11
3	Pan-cancer proteomic map of 949 human cell lines. <i>Cancer Cell</i> , 2022, 40, 835-849.e8.	16.8	52
4	AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 238-249.	4.1	13
5	Project Score database: a resource for investigating cancer cell dependencies and prioritizing therapeutic targets. <i>Nucleic Acids Research</i> , 2021, 49, D1365-D1372.	14.5	54
6	Cancer research needs a better map. <i>Nature</i> , 2021, 589, 514-516.	27.8	57
7	Integrated cross-study datasets of genetic dependencies in cancer. <i>Nature Communications</i> , 2021, 12, 1661.	12.8	135
8	Use of preclinical models for malignant pleural mesothelioma. <i>Thorax</i> , 2021, 76, 1154-1162.	5.6	16
9	Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy. <i>Cancer Discovery</i> , 2021, 11, 1923-1937.	9.4	48
10	MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia. <i>Cancer Research</i> , 2021, 81, 5733-5744.	0.9	15
11	Inferred Ancestral Origin of Cancer Cell Lines Associates with Differential Drug Response. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10135.	4.1	2
12	Minimal genome-wide human CRISPR-Cas9 library. <i>Genome Biology</i> , 2021, 22, 40.	8.8	40
13	Combinatorial CRISPR screen identifies fitness effects of gene paralogues. <i>Nature Communications</i> , 2021, 12, 1302.	12.8	59
14	CoRe: a robustly benchmarked R package for identifying core-fitness genes in genome-wide pooled CRISPR-Cas9 screens. <i>BMC Genomics</i> , 2021, 22, 828.	2.8	14
15	AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia. <i>Clinical Cancer Research</i> , 2020, 26, 6535-6549.	7.0	42
16	CELLector: Genomics-Guided Selection of Cancer In Vitro Models. <i>Cell Systems</i> , 2020, 10, 424-432.e6.	6.2	35
17	Genomics-guided pre-clinical development of cancer therapies. <i>Nature Cancer</i> , 2020, 1, 482-492.	13.2	23
18	Patient-specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies. <i>Molecular Systems Biology</i> , 2020, 16, e8664.	7.2	60

#	ARTICLE	IF	CITATIONS
19	Drug mechanism of action discovery through the integration of pharmacological and CRISPR screens. <i>Molecular Systems Biology</i> , 2020, 16, e9405.	7.2	63
20	Genome-wide CRISPR screens of oral squamous cell carcinoma reveal fitness genes in the Hippo pathway. <i>ELife</i> , 2020, 9, .	6.0	31
21	A statistical framework for assessing pharmacological responses and biomarkers using uncertainty estimates. <i>ELife</i> , 2020, 9, .	6.0	16
22	Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6243-6259.	7.0	42
23	Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen. <i>Nature Communications</i> , 2019, 10, 2674.	12.8	240
24	Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening. <i>Nature Communications</i> , 2019, 10, 2198.	12.8	92
25	Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals Episodic APOBEC Mutagenesis. <i>Cell</i> , 2019, 176, 1282-1294.e20.	28.9	298
26	Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. <i>Nature</i> , 2019, 568, 511-516.	27.8	886
27	Structural rearrangements generate cell-specific, gene-independent CRISPR-Cas9 loss of fitness effects. <i>Genome Biology</i> , 2019, 20, 27.	8.8	35
28	Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets. <i>Nature Communications</i> , 2019, 10, 5817.	12.8	160
29	Pancreatic cancer organoids recapitulate disease and allow personalized drug screening. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 26580-26590.	7.1	279
30	NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263. <i>Clinical Cancer Research</i> , 2019, 25, 312-324.	7.0	11
31	Cell Model Passports—a hub for clinical, genetic and functional datasets of preclinical cancer models. <i>Nucleic Acids Research</i> , 2019, 47, D923-D929.	14.5	118
32	Discovery of Potent and Selective MRCK Inhibitors with Therapeutic Effect on Skin Cancer. <i>Cancer Research</i> , 2018, 78, 2096-2114.	0.9	31
33	GDSCTools for mining pharmacogenomic interactions in cancer. <i>Bioinformatics</i> , 2018, 34, 1226-1228.	4.1	45
34	Perturbation-response genes reveal signaling footprints in cancer gene expression. <i>Nature Communications</i> , 2018, 9, 20.	12.8	436
35	Transcription Factor Activities Enhance Markers of Drug Sensitivity in Cancer. <i>Cancer Research</i> , 2018, 78, 769-780.	0.9	161
36	Itraconazole targets cell cycle heterogeneity in colorectal cancer. <i>Journal of Experimental Medicine</i> , 2018, 215, 1891-1912.	8.5	54

#	ARTICLE	IF	CITATIONS
37	Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics. <i>Nature Communications</i> , 2018, 9, 2983.	12.8	206
38	The germline genetic component of drug sensitivity in cancer cell lines. <i>Nature Communications</i> , 2018, 9, 3385.	12.8	38
39	Unsupervised correction of gene-independent cell responses to CRISPR-Cas9 targeting. <i>BMC Genomics</i> , 2018, 19, 604.	2.8	75
40	A Road Map for Precision Cancer Medicine Using Personalized Models. <i>Cancer Discovery</i> , 2017, 7, 456-458.	9.4	9
41	Drug Resistance Mechanisms in Colorectal Cancer Dissected with Cell Type-Specific Dynamic Logic Models. <i>Cancer Research</i> , 2017, 77, 3364-3375.	0.9	101
42	High-throughput RNAi screen for essential genes and drug synergistic combinations in colorectal cancer. <i>Scientific Data</i> , 2017, 4, 170139.	5.3	11
43	Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. <i>Nature Medicine</i> , 2017, 23, 1424-1435.	30.7	905
44	A Landscape of Pharmacogenomic Interactions in Cancer. <i>Cell</i> , 2016, 166, 740-754.	28.9	1,518
45	Multilevel models improve precision and speed of IC ₅₀ estimates. <i>Pharmacogenomics</i> , 2016, 17, 691-700.	1.3	57
46	Logic models to predict continuous outputs based on binary inputs with an application to personalized cancer therapy. <i>Scientific Reports</i> , 2016, 6, 36812.	3.3	43
47	Drug Sensitivity Assays of Human Cancer Organoid Cultures. <i>Methods in Molecular Biology</i> , 2016, 1576, 339-351.	0.9	54
48	A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. <i>Cell</i> , 2016, 167, 260-274.e22.	28.9	376
49	Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen. <i>Oncotarget</i> , 2016, 7, 22128-22139.	1.8	21
50	Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma. <i>PLoS ONE</i> , 2015, 10, e0140988.	2.5	72
51	Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients. <i>Cell</i> , 2015, 161, 933-945.	28.9	1,710
52	What role could organoids play in the personalization of cancer treatment?. <i>Pharmacogenomics</i> , 2015, 16, 1523-1526.	1.3	11
53	Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. <i>Nucleic Acids Research</i> , 2012, 41, D955-D961.	14.5	2,363
54	Systematic identification of genomic markers of drug sensitivity in cancer cells. <i>Nature</i> , 2012, 483, 570-575.	27.8	2,173

#	ARTICLE	IF	CITATIONS
55	Can Drug Repurposing Accelerate Precision Oncology?. Cancer Discovery, 0, , OF1-OF8.	9.4	11